Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TD-1439 in healthy subjects
NCT02903095Phase 1Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Sep 2016
- Primary completion
- Dec 2016
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in heart failure (HF), hypertension (HTN) and chronic kidney disease (CKD) comparing TD-1439 Arm with Placebo Arm (2 arms). Primary endpoint: Safety of TD-1439 by assessing the number and severity of adverse events. Started Sep 2016; status: completed.
02
Drugs
TD-1439
03
Conditions
heart failure (HF)hypertension (HTN)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02903095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02903095.